上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2014年
2期
24-26
,共3页
蛋白尿%原发性高血压%治疗结果%安全%厄贝沙坦
蛋白尿%原髮性高血壓%治療結果%安全%阨貝沙坦
단백뇨%원발성고혈압%치료결과%안전%액패사탄
proteinuria%primary hypertension%treatment outcome%safety%irbesartan
目的：观察厄贝沙坦对原发性高血压患者的降压作用及对蛋白尿的影响。方法：将100例轻中度原发性高血压伴蛋白尿患者于停药l周后给予厄贝沙坦，每次150 mg，每日1次，共治疗3个月。观察患者治疗前后血压、24 h尿蛋白定量、肾功能及血β2微球蛋白的变化。结果：治疗3个月后，收缩压由治疗前的(151.0±13.7) mm Hg降至(130.7±15.8) mmHg，差异有统计学意义(t=2.51, P<0.05)；舒张压由治疗前的(94.9±10.6) mmHg下降至(84.5±6.3) mmHg，差异有统计学意义(t=2.95, P<0.01)。24 h尿蛋白定量由(1.49±0.59) g降至(0.64±0.43) g，差异有统计学意义(t=2.83, P<0.01)；血β2微球蛋白由(3.22±2.71) mg/L降至(2.13士1.82) mg/L，差异有统计学意义(t=2.57, P<0.05)。结论：厄贝沙坦治疗原发性高血压患者降压效果确切，能显著降低尿蛋白，改善肾功能。
目的：觀察阨貝沙坦對原髮性高血壓患者的降壓作用及對蛋白尿的影響。方法：將100例輕中度原髮性高血壓伴蛋白尿患者于停藥l週後給予阨貝沙坦，每次150 mg，每日1次，共治療3箇月。觀察患者治療前後血壓、24 h尿蛋白定量、腎功能及血β2微毬蛋白的變化。結果：治療3箇月後，收縮壓由治療前的(151.0±13.7) mm Hg降至(130.7±15.8) mmHg，差異有統計學意義(t=2.51, P<0.05)；舒張壓由治療前的(94.9±10.6) mmHg下降至(84.5±6.3) mmHg，差異有統計學意義(t=2.95, P<0.01)。24 h尿蛋白定量由(1.49±0.59) g降至(0.64±0.43) g，差異有統計學意義(t=2.83, P<0.01)；血β2微毬蛋白由(3.22±2.71) mg/L降至(2.13士1.82) mg/L，差異有統計學意義(t=2.57, P<0.05)。結論：阨貝沙坦治療原髮性高血壓患者降壓效果確切，能顯著降低尿蛋白，改善腎功能。
목적：관찰액패사탄대원발성고혈압환자적강압작용급대단백뇨적영향。방법：장100례경중도원발성고혈압반단백뇨환자우정약l주후급여액패사탄，매차150 mg，매일1차，공치료3개월。관찰환자치료전후혈압、24 h뇨단백정량、신공능급혈β2미구단백적변화。결과：치료3개월후，수축압유치료전적(151.0±13.7) mm Hg강지(130.7±15.8) mmHg，차이유통계학의의(t=2.51, P<0.05)；서장압유치료전적(94.9±10.6) mmHg하강지(84.5±6.3) mmHg，차이유통계학의의(t=2.95, P<0.01)。24 h뇨단백정량유(1.49±0.59) g강지(0.64±0.43) g，차이유통계학의의(t=2.83, P<0.01)；혈β2미구단백유(3.22±2.71) mg/L강지(2.13사1.82) mg/L，차이유통계학의의(t=2.57, P<0.05)。결론：액패사탄치료원발성고혈압환자강압효과학절，능현저강저뇨단백，개선신공능。
Objective:To observe the antihypertensive effect of irbesartan to primary hypertension and its impact on proteinuria. Methods:Irbesartan for 100 cases of patients with mild and moderate primary hypertension and proteinuria was administrated at 150 mg each time and once a day for 3 months one week after drug withdrawal. The changes of blood pressure, 24 h urine protein, renal function and serumβ2-microglobulin were observed before and after treatments. Results:After 3 months of treatment, systolic blood pressure fell from (151±13.7) mmHg before treatment to (130.7±15.8) mmHg, and the difference had statistical signiifcance (t=2.51, P<0.05). Diastolic pressure fell from (94.9±10.6) mmHg before treatment to (84.5±6.3) mmHg, and the difference had statistical signiifcance (t=2.95, P<0.01). 24 h urine protein quantitation fell from (1.49 ± 0.59) g to (0.64 ± 0.43) g, the difference had statistical signiifcance (t=2.83, P<0.01). Beta 2 microglobulin fell from (3.22±2.71) mg/L to (2.13±1.82) mg/L, the difference had statistical signiifcance (t=2.57, P<0.05). Conclusion:Irbesartan has the exact antihypertensive effect in the treatment of primary hypertension, can signiifcantly reduce urinary protein and improve renal function.
